- Home
- SGMT vs PMX Comparison
SGMT vs PMX Comparison
Compare SGMT & PMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- PMX
- Stock Information
- Founded
- SGMT 2006
- PMX 2002
- Country
- SGMT United States
- PMX United States
- Employees
- SGMT N/A
- PMX N/A
- Industry
- SGMT
- PMX Trusts Except Educational Religious and Charitable
- Sector
- SGMT
- PMX Finance
- Exchange
- SGMT Nasdaq
- PMX Nasdaq
- Market Cap
- SGMT 269.2M
- PMX 233.7M
- IPO Year
- SGMT 2023
- PMX N/A
- Fundamental
- Price
- SGMT $10.94
- PMX $6.62
- Analyst Decision
- SGMT Strong Buy
- PMX
- Analyst Count
- SGMT 6
- PMX 0
- Target Price
- SGMT $26.83
- PMX N/A
- AVG Volume (30 Days)
- SGMT 883.6K
- PMX 101.5K
- Earning Date
- SGMT 08-13-2025
- PMX 01-01-0001
- Dividend Yield
- SGMT N/A
- PMX 5.28%
- EPS Growth
- SGMT N/A
- PMX N/A
- EPS
- SGMT N/A
- PMX N/A
- Revenue
- SGMT N/A
- PMX N/A
- Revenue This Year
- SGMT N/A
- PMX N/A
- Revenue Next Year
- SGMT N/A
- PMX N/A
- P/E Ratio
- SGMT N/A
- PMX N/A
- Revenue Growth
- SGMT N/A
- PMX N/A
- 52 Week Low
- SGMT $1.73
- PMX $6.09
- 52 Week High
- SGMT $10.99
- PMX $8.47
- Technical
- Relative Strength Index (RSI)
- SGMT 68.84
- PMX 36.89
- Support Level
- SGMT $8.79
- PMX $6.61
- Resistance Level
- SGMT $10.99
- PMX $6.69
- Average True Range (ATR)
- SGMT 0.74
- PMX 0.05
- MACD
- SGMT -0.05
- PMX -0.01
- Stochastic Oscillator
- SGMT 82.20
- PMX 16.67
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.